Intratumoral heterogeneity as a confounding factor in clonogenic assays for tumour radioresponsiveness

被引:46
作者
Britten, RA
Evans, AJ
AllalunisTurner, MJ
Franko, AJ
Pearcey, RG
机构
[1] CROSS CANC INST,DEPT RADIAT ONCOL,EDMONTON,AB T6G 1Z2,CANADA
[2] UNIV ALBERTA,DEPT ONCOL,EDMONTON,AB,CANADA
关键词
heterogeneity; radiosensitivity; predictive assays; cervical cancer;
D O I
10.1016/0167-8140(96)01719-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The level of intra-tumoral heterogeneity of cellular radiosensitivity within primary cultures of three carcinomas of the cervix has been established, All three cultures contained clones that varied by as much as 3-fold in their clinically relevant radiosensitivity (SF2). The level of intra-tumoral heterogeneity observed in these cervical tumour cultures was sufficient to be a major confounding factor to the use of pre-treatment assessments of radiosensitivity to predict for clinical radioresponsiveness. Mathematical modeling of the relative elimination of the tumour clones during fractionated radiotherapy indicates that, in two of the three biopsy samples, the use of pre-treatment derived SF2 values from the heterogeneous tumour sample would significantly overestimate radioresponsiveness, We conclude that assays of cellular radiosensitivity that identify the radiosensitivity of the most radioresistant clones and measure their relative abundance could potentially increase the effectiveness of SF2 values as a predictive marker of radioresponsiveness.
引用
收藏
页码:145 / 153
页数:9
相关论文
共 41 条
[1]   ISOLATION OF 2 CELL-LINES FROM A HUMAN-MALIGNANT GLIOMA SPECIMEN DIFFERING IN SENSITIVITY TO RADIATION AND CHEMOTHERAPEUTIC DRUGS [J].
ALLALUNISTURNER, MJ ;
BARRON, GM ;
DAY, RS ;
DOBLER, KD ;
MIRZAYANS, R .
RADIATION RESEARCH, 1993, 134 (03) :349-354
[2]   INHERENT RADIOSENSITIVITY TESTING OF TUMOR-BIOPSIES OBTAINED FROM PATIENTS WITH CARCINOMA OF THE CERVIX OR ENDOMETRIUM [J].
ALLALUNISTURNER, MJ ;
PEARCEY, RG ;
BARRON, GM ;
BURYN, DA ;
BABIAK, JC ;
HONORE, LH .
RADIOTHERAPY AND ONCOLOGY, 1991, 22 (03) :201-205
[3]   INTRATUMORAL HETEROGENEITY OF MALIGNANT GLIOMAS MEASURED IN-VITRO [J].
ALLAM, A ;
TAGHIAN, A ;
GIOIOSO, D ;
DUFFY, M ;
SUIT, HD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 27 (02) :303-308
[4]   RANDOMIZED TRIAL OF 3 CISPLATIN DOSE SCHEDULES IN SQUAMOUS-CELL CARCINOMA OF THE CERVIX - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].
BONOMI, P ;
BLESSING, JA ;
STEHMAN, FB ;
DISAIA, PJ ;
WALTON, L ;
MAJOR, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (08) :1079-1085
[5]   DENOVO CISPLATINUM RESISTANCE DOES NOT INFLUENCE CELLULAR RADIOSENSITIVITY [J].
BRITTEN, RA ;
WARENIUS, HM .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (09) :1315-1320
[6]   Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinoma cell lines [J].
Britten, RA ;
Evans, AJ ;
AllalunisTurner, MJ ;
Pearcey, RG .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 34 (02) :367-374
[7]  
BROWN JM, 1992, INT J RADIAT ONCOL, V24, P279, DOI 10.1016/0360-3016(92)90682-8
[8]   PREDICTION OF NORMAL-TISSUE TOLERANCE TO RADIOTHERAPY FROM INVITRO CELLULAR RADIATION SENSITIVITY [J].
BURNET, NG ;
NYMAN, J ;
TURESSON, I ;
WURM, R ;
YARNOLD, JR ;
PEACOCK, JH .
LANCET, 1992, 339 (8809) :1570-1571
[9]   THE RELATIONSHIP BETWEEN CELLULAR RADIATION SENSITIVITY AND TISSUE-RESPONSE MAY PROVIDE THE BASIS FOR INDIVIDUALIZING RADIOTHERAPY SCHEDULES [J].
BURNET, NG ;
NYMAN, J ;
TURESSON, I ;
WURM, R ;
YARNOLD, JR ;
PEACOCK, JH .
RADIOTHERAPY AND ONCOLOGY, 1994, 33 (03) :228-238
[10]   USE OF FLUORESCENCE IN-SITU HYBRIDIZATION TO MEASURE CHROMOSOME-ABERRATIONS AS A PREDICTOR OF RADIOSENSITIVITY IN HUMAN TUMOR-CELLS [J].
COCOMARTIN, JM ;
SMEETS, MFMA ;
POGGENSEE, M ;
MOOREN, E ;
HOFLAND, I ;
VANDENBRUG, M ;
OTTENHEIM, C ;
BARTELINK, H ;
BEGG, AC .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1994, 66 (03) :297-307